Concepedia

An antibody–cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours

Rebecca K. Kelly, Dian L. Olson, Yaping Sun, Dingyi Wen, Kathleen Wortham, Giovanna Antognetti, Anne E. Cheung, Olivia Orozco, Yang Lü, Véronique Bailly,

European Journal of Cancer · 2011 · 43 citations · 30 references

DOI

Concepts

References

30

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.7K citations

, , +17

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text

, , +17

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2010 · 764 citations · Full text

, , +17

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 596 citations

, , +17

Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing

Hans K. Erickson, Peter U. Park, Wayne C. Widdison et al. · Cancer Research · 2006 · 574 citations · Full text

, , +14